after agreeing to join the study, you sign a consent form that explains the purpose of the trial, the treatments you will receive, and your rights as a participant.

the study team assigns you to one of two groups: the test group, which receives atebimetinib together with modified gemcitabine and nab-paclitaxel, or the comparator group, which receives only gemcitabine and nab-paclitaxel.

before starting treatment, you undergo blood tests, imaging scans, and other examinations to document the current status of your disease.

on the first day of the cycle you receive two intravenous (through a vein) infusions:

gemcitabine 1000 mg per square meter of body surface area (mg/m2) given by infusion,

nab-paclitaxel 125 mg per square meter (mg/m2) given by infusion.

if you are in the test group, you also start taking atebimetinib 320 mg by mouth (oral tablet) each day.

the same set of medications is repeated in each cycle according to the study schedule, which is defined by the trial protocol.

each cycle continues until the protocol specifies a stop, such as disease progression, unacceptable side effects, or the end of the planned treatment period.

throughout the study you attend scheduled visits for blood work, imaging, and clinical evaluation to monitor how the disease is responding and to check for side effects.

when treatment is stopped, you continue to have follow‑up visits as outlined in the protocol to assess long‑term outcomes and overall survival.